Company news
Hoth Therapeutics, Inc. news in 2021
Hoth Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Hoth Therapeutics Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis
December 20, 2021
Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics
December 7, 2021
Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT
November 15, 2021
Hoth Therapeutics Inks API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT Cancer Therapeutic
November 7, 2021
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
October 18, 2021
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients
October 11, 2021
Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial
September 20, 2021
Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa
September 7, 2021
Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease
August 1, 2021
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne
July 12, 2021
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
June 27, 2021
Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ
June 6, 2021
Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic
June 2, 2021
Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2021
Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers
May 2, 2021
Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway
April 21, 2021
Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived Cancers
April 19, 2021
Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical Trial
April 11, 2021
Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients
April 5, 2021
Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm
April 4, 2021
Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 Therapeutic
March 22, 2021
Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006
March 16, 2021
Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease
March 10, 2021
Hoth Therapeutics Completes Closing of Previously Announced $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 9, 2021
Hoth Therapeutics Announces $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 7, 2021
Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies
March 2, 2021
Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
February 28, 2021
Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment
February 23, 2021
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients
February 22, 2021
Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)
February 17, 2021
Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients
February 7, 2021
Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline
February 1, 2021
Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research
January 27, 2021
Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board
January 26, 2021
Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication
January 19, 2021
FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients
January 12, 2021
Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients
January 10, 2021
Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules
January 4, 2021
Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections
January 3, 2021